P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
Main Authors: | Hila Magen, Shalev Fried, Orit Itzhaki, Noga Shem-Tov, Ivetta Danylesko, Ronit Yerushalmi, Roni Shouval, Ronit Marcus, Lee Nevo, Ronnie Shapira-Frommer, Arnon Nagler, Avichai Shimoni, Eden Shkury, Avigdor Abraham |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000970460.94543.ab |
Similar Items
-
P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
by: Ivetta Danylesko, et al.
Published: (2023-08-01) -
P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE
by: Mika Geva, et al.
Published: (2023-08-01) -
P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
by: S. Fried, et al.
Published: (2022-06-01) -
Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders.
by: Hila Magen, et al.
Published: (2023-01-01) -
Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies
by: Katia Beider, et al.
Published: (2022-03-01)